News
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab i...
The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanof